Georgios Sioutas, MD (@gssioutas) 's Twitter Profile
Georgios Sioutas, MD

@gssioutas

Postdoc Researcher @VCUNeuro 🇺🇸 | MD 🇬🇷

ID: 1636106100847124483

linkhttps://www.linkedin.com/in/georgios-sioutas-md/ calendar_today15-03-2023 20:44:46

109 Tweet

419 Followers

1,1K Following

Stepan M. Esagian, MD (@sm_esagian) 's Twitter Profile Photo

Absolutely thrilled to share that I’ve matched at MD Anderson for my hematology/oncology fellowship! Immensely grateful to my mentors for their unwavering support in helping me overcome the challenges faced by non-US IMGs and achieve this dream! #MatchDay #JacobiStrong

Absolutely thrilled to share that I’ve matched at MD Anderson for my hematology/oncology fellowship! Immensely grateful to my mentors for their unwavering support in helping me overcome the challenges faced by non-US IMGs and achieve this dream!  #MatchDay #JacobiStrong
Georgios Sioutas, MD (@gssioutas) 's Twitter Profile Photo

Honored to present my work on GLP-1 RAs and post-stroke outcomes in obese patients at #AANS2025 AANS in Boston, and grateful to receive the Cerebrovascular Section Best Clinical Abstract Award, presented by Stavropoula Tjoumakaris MD, MBA, FAANS, FACS, FAHA. Thankful to my mentors at VCU Neurology & Neurosurgery Dennis J Rivet II MD.

Honored to present my work on GLP-1 RAs and post-stroke outcomes in obese patients at #AANS2025 <a href="/AANSNeuro/">AANS</a> in Boston, and grateful to receive the Cerebrovascular Section Best Clinical Abstract Award, presented by <a href="/StavTjoumakaris/">Stavropoula Tjoumakaris MD, MBA, FAANS, FACS, FAHA</a>. Thankful to my mentors at <a href="/VCUNeuro/">VCU Neurology & Neurosurgery</a> <a href="/rivetdj/">Dennis J Rivet II MD</a>.
@RadiologyEditor (@radiologyeditor) 's Twitter Profile Photo

When’s the best time for middle meningeal artery embolization in chronic subdural hematoma? ⏰🧠 This study by Ramesh Grandhi, Georgios Sioutas, MD and team found no outcome differences based on timing. Useful data for surgical planning! #NeuroRad #Radiology pubs.rsna.org/doi/10.1148/ra…

When’s the best time for middle meningeal artery embolization in chronic subdural hematoma? ⏰🧠 This study by <a href="/rgrandhi/">Ramesh Grandhi</a>, <a href="/GSSioutas/">Georgios Sioutas, MD</a> and team found no outcome differences based on timing. Useful data for surgical planning! #NeuroRad #Radiology
pubs.rsna.org/doi/10.1148/ra…
Mohamed M. Salem, MD MPH (@mmsalemmd) 's Twitter Profile Photo

Great to see our recent study on #MMAE embolic materials comparison selected as #NEUEditorsChoice in the Red Journal Jan-Karl Burkhardt, MD Penn Neurosurgery CU Neurosurgery. Many thanks to our collaborators and to Neurosurgery Publications for highlighting our work! CNS #Neurosurgery

Santiago Gomez-Paz, MD (@santiagogpmd) 's Twitter Profile Photo

New study on Chronic Subdural Hematomas is out! 👉🏽 journals.sagepub.com/doi/10.1177/15… Published in Interventional Neuroradiology Interventional Neuroradiology : examines whether outcomes after middle meningeal artery embolization (MMAE) for chronic subdural hematoma differ across racial groups. ▪

New study on Chronic Subdural Hematomas is out! 👉🏽 journals.sagepub.com/doi/10.1177/15…

Published in Interventional Neuroradiology <a href="/INR_WFITN/">Interventional Neuroradiology</a> : examines whether outcomes after middle meningeal artery embolization (MMAE) for chronic subdural hematoma differ across racial groups.

▪
Visish M. Srinivasan, MD (@visishs) 's Twitter Profile Photo

Congrats Avi Gajjar on another article in Interventional Neuroradiology demonstrating the value of MMAE in a unique population not addressed in the recent trials: patients with cancer. Relatively comparable results in this group compared to non-cancer population. journals.sagepub.com/doi/abs/10.117…

Avi Gajjar (@aviagajjar) 's Twitter Profile Photo

Excited to share this study on MMAE in cancer patients: a vulnerable patient population that can stand to benefit the most from MMAE, but are excluded from recent RCTs based on the nature of their disease. It is encouraging to see sustained efficacy of MMAE in this high-risk

Excited to share this study on MMAE in cancer patients: a vulnerable patient population that can stand to benefit the most from MMAE, but are excluded from recent RCTs based on the nature of their disease. It is encouraging to see sustained efficacy of MMAE in this high-risk
JAMA Neurology (@jamaneuro) 's Twitter Profile Photo

Authors Dennis J Rivet II MD and William Mualem discuss "GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension" with JAMA Neurology Web Editor Cynthia Armand. ja.ma/44O7KNb

JAMA Neurology (@jamaneuro) 's Twitter Profile Photo

Most viewed this week from JAMA Neurology: GLP-1 RA therapy may offer an alternative management strategy for idiopathic intracranial hypertension. ja.ma/40TkzDy

Most viewed this week from <a href="/JAMANeuro/">JAMA Neurology</a>: 

GLP-1 RA therapy may offer an alternative management strategy for idiopathic intracranial hypertension. 

ja.ma/40TkzDy
JAMA Neurology (@jamaneuro) 's Twitter Profile Photo

Most viewed this week from JAMA Neurology: GLP-1 RA therapy may offer an alternative management strategy for idiopathic intracranial hypertension. ja.ma/44GniCQ

Most viewed this week from <a href="/JAMANeuro/">JAMA Neurology</a>: 

GLP-1 RA therapy may offer an alternative management strategy for idiopathic intracranial hypertension. 

ja.ma/44GniCQ
JAMA Neurology (@jamaneuro) 's Twitter Profile Photo

Most viewed this week from JAMA Neurology: GLP-1 RA therapy may offer an alternative management strategy for idiopathic intracranial #hypertension. ja.ma/4lGhEGJ

Most viewed this week from <a href="/JAMANeuro/">JAMA Neurology</a>: 

GLP-1 RA therapy may offer an alternative management strategy for idiopathic intracranial #hypertension. 

ja.ma/4lGhEGJ